Advertisement


Bernd Kasper, MD, PhD, on Desmoid Tumors: Results on Nirogacestat vs Placebo

ESMO Congress 2022

Advertisement

Bernd Kasper, MD, PhD, of Germany’s Mannheim Cancer Center, discusses phase III data from the DeFi trial, the largest study conducted to date for patients with desmoid tumors. The trial showed that the gamma secretase inhibitor nirogacestat demonstrated improvements in all primary and secondary efficacy endpoints. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and, occasionally, mortality in patients (Abstract LBA2).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
It's my pleasure to speak about DeFi phase III trial of nirogacestat in progressing desmoid tumor patients and I had the pleasure to present that trial yesterday at ESMO 2022 in the presidential session. When talking about desmoid tumors, we are actually talking about a rare disease. They are locally aggressive and invasive soft tissue tumors that are somehow difficult to manage due to their variable presentations, the unpredictable clinical cause, and the lack of currently approved therapies. There is indeed a clear rationale for the use of gamma secretase inhibitors in this disease as desmoid tumors express [inaudible 00:00:47], which can be blocked by gamma secretase inhibitors. So nirogacestat is an investigational oral and selective small molecule gamma secretase inhibitor that already showed activity in phase I and II trials in desmoid tumors with a manageable safety profile. The phase III trial is a large global randomized double blind placebo-controlled trial, looking at safety, efficacy and tolerability of nirogacestat in comparison to placebo in resist progressing desmoid tumors. We actually randomized 142 patients in 37 sites all over the world and primary endpoint was progression-free survival and secondary endpoints included overall response rate, and a couple of different patient-reported outcome measures. So the results are as follows. The primary endpoint was met with improved progression-free survival, demonstrating a statistically significant 71% reduction in the risk of disease progression. And the confirmed objective response rate was 41% with nirogacestat as compared to 8% in the placebo arm. Again, highly statistically significant, including 7% complete responses with nirogacestat. The median time to response was 5.6 months with nirogacestat compared to 11 month in the placebo arm. In terms of safety, actually nirogacestat was well tolerated. 95% of all treatment emergent adverse events were grade I or II. The most frequent side effect with nirogacestat were diarrhea, rash, hyperphosphatemia and fatigue. And those reductions were necessary in about 40% of patients and were primarily due to diarrhea, rash, and stomatitis. In summary, DeFi represents the largest and most rigorous randomized controlled trial to-date in desmoid tumor. It actually definitely showed rapid, sustained and statistically significant improvements in all primary and secondary endpoints. It had a manageable safety profile with 95% of all the treatment emergent adverse events being grade I or II, and nirogacestat does have the potential to become the standard of care in desmoid tumors requiring systemic treatment. There are definitely a couple of open questions still from that trial. One question might be the lengths of treatment duration so there could be something like a discontinuation trial. But what we'd learned from that trial already that nirogacestat is absolutely feasible for long-term treatment in this patient population and we will investigate, of course, a lot of other questions as well.

Related Videos

Prostate Cancer

Rahul Aggarwal, MD, on Prostate Cancer: Phase III Data on Apalutamide and Androgen Deprivation in Relapsed Disease

Rahul Aggarwal, MD, of the University of California, San Francisco, discusses recent data from the PRESTO study, which showed that apalutamide plus androgen-deprivation therapy (ADT) for 12 months significantly prolonged PSA progression-free survival compared with ADT alone in patients with biochemically recurrent prostate cancer. These results provide support for the intensification of ADT in this setting. (Abstract LBA63).

Kidney Cancer

Thomas Powles, MD, PhD, and Christopher Sweeney, MBBS, on RCC: Expert Review of Two Key Studies on Atezolizumab, Nivolumab, and Ipilimumab

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss two important phase III studies on renal cell cancer (RCC) presented at ESMO 2022: IMmotion010, which examined the efficacy and safety of atezolizumab vs placebo as adjuvant therapy in patients with RCC at increased risk of recurrence after nephrectomy; and CheckMate 914, which compared nivolumab monotherapy or nivolumab combined with ipilimumab vs placebo in patients with localized disease who underwent radical or partial nephrectomy and who are at high risk of relapse. (Abstract LBA4 & LBA66).

Kidney Cancer
Immunotherapy

Robert J. Motzer, MD, on Renal Cell Carcinoma: New Results With Nivolumab and Ipilimumab

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CheckMate 914 trial, which explored the efficacy of adjuvant nivolumab plus ipilimumab vs placebo in the treatment of patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (Abstract LBA4).

Breast Cancer

Laurence Buisseret, MD, PhD, on Triple-Negative Breast Cancer: Chemoimmunotherapy With or Without an Anti-CD73 Antibody

Laurence Buisseret, MD, PhD, of Belgium’s Institut Jules Bordet, discusses phase II results from the SYNERGY trial, which tested first-line chemoimmunotherapy of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer. Although adding oleclumab to durvalumab with chemoimmunotherapy did not increase the clinical benefit rate at week 24, research is ongoing to better understand the mechanisms of response and resistance to this study combination (Abstract LBA17).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Recent Phase III Data on Cabozantinib, Nivolumab, and Ipilimumab From the COSMIC-313 Trial

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss phase III findings showing that cabozantinib in combination with nivolumab and ipilimumab reduced the risk of disease progression or death compared with the combination of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma of IMDC (the International Metastatic RCC Database Consortium) intermediate or poor risk. However, the combination of cabozantinib, nivolumab, and ipilimumab vs nivolumab plus ipilimumab did not demonstrate an overall survival benefit to patients (Abstract LBA8).

Advertisement

Advertisement




Advertisement